Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Development and use of FRAX in osteoporosis.

Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F.

Osteoporos Int. 2010 Jun;21 Suppl 2:S407-13. doi: 10.1007/s00198-010-1253-y. Epub 2010 May 13. Review.

PMID:
20464374
2.

[FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].

Johansson H, Kanis JA, Ljunggren O, Ström O, Svensson O, Mellström D.

Lakartidningen. 2011 Feb 16-22;108(7):336-9. Review. Swedish. No abstract available.

PMID:
21539116
3.

How to decide who to treat.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A.

Best Pract Res Clin Rheumatol. 2009 Dec;23(6):711-26. doi: 10.1016/j.berh.2009.09.002. Review.

PMID:
19945684
4.

Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.

Siris ES, Baim S, Nattiv A.

Postgrad Med. 2010 Jan;122(1):82-90. doi: 10.3810/pgm.2010.01.2102. Review.

PMID:
20107292
5.

[Usefulness of FRAX and future issues in women's health].

Hashimoto K, Ishitani K, Ohta H.

Clin Calcium. 2009 Dec;19(12):1742-8. doi: CliCa091217421744. Review. Japanese.

PMID:
19949265
6.

[Recommendations of FRAX in clinical assessment of osteoporosis indicated in European and US guidelines].

Nakamura T.

Clin Calcium. 2009 Dec;19(12):1723-8. doi: CliCa091217231728. Review. Japanese.

PMID:
19949262
8.

[Application of FRAX for health check-ups].

Fujiwara S.

Clin Calcium. 2009 Dec;19(12):1730-4. doi: CliCa091217301734. Review. Japanese.

PMID:
19949263
9.
11.

FRAX updates 2012.

McCloskey E, Kanis JA.

Curr Opin Rheumatol. 2012 Sep;24(5):554-60. doi: 10.1097/BOR.0b013e328356d2f5. Review.

PMID:
22820516
12.

Strontium ranelate: an effective solution for diverse fracture risks.

Ringe JD.

Osteoporos Int. 2010 Jun;21 Suppl 2:S431-6. doi: 10.1007/s00198-010-1241-2. Epub 2010 May 13. Review.

PMID:
20464377
13.

Fracture risk assessment in Latin America: is Frax an adaptable instrument for the region?

Morales-Torres J, Clark P, Delezé-Hinojosa M, Cons-Molina F, Messina OD, Hernández J, Jaller-Raad JJ, Quevedo-Solidoro H, Radominski SC.

Clin Rheumatol. 2010 Oct;29(10):1085-91. doi: 10.1007/s10067-010-1489-0. Epub 2010 Jul 15. Review.

PMID:
20632196
14.

Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.

Silverman SL, Komm BS, Mirkin S.

Maturitas. 2014 Nov;79(3):241-7. doi: 10.1016/j.maturitas.2014.07.007. Epub 2014 Jul 16. Review.

PMID:
25124532
15.

Real-world challenges of treating osteoporosis.

Owens G.

Am J Manag Care. 2011 May;17 Suppl 6:S177-84. Review.

PMID:
21882487
16.

Addressing the age-related needs of osteoporotic patients with strontium ranelate.

Boonen S.

Osteoporos Int. 2010 Jun;21 Suppl 2:S415-23. doi: 10.1007/s00198-010-1231-4. Epub 2010 May 13. Review.

PMID:
20464375
17.

Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis.

Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB.

Pharmacotherapy. 2006 Jan;26(1):104-14. Review.

PMID:
16506352
18.

Prevention and treatment of senile osteoporosis and hip fractures.

Duque G, Demontiero O, Troen BR.

Minerva Med. 2009 Feb;100(1):79-94. Review.

PMID:
19277006
19.

Predicting the fracture risk in 2008.

Fardellone P.

Joint Bone Spine. 2008 Dec;75(6):661-4. doi: 10.1016/j.jbspin.2008.09.002. Epub 2008 Nov 22. Review.

PMID:
19028433
20.

A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture.

White HJ, Bettiol SS, Perera R, Roberts NW, Javaid MK, Farmer AJ.

Fam Pract. 2010 Dec;27(6):593-603. doi: 10.1093/fampra/cmq060. Epub 2010 Aug 6. Review.

PMID:
20693238

Supplemental Content

Support Center